vs
OppFi Inc.（OPFI）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是OppFi Inc.的1.5倍（$127.1M vs $85.6M），再鼎医药同比增速更快（17.1% vs 5.9%），OppFi Inc.自由现金流更多（$382.2M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 16.3%）
OppFi Inc.是一家总部位于美国的金融科技公司，面向传统银行服务覆盖不足的消费者群体，提供分期贷款、信用建设工具等负责任的普惠金融产品，助力用户改善长期财务健康状况。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
OPFI vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.5倍
$85.6M
营收增速更快
ZLAB
高出11.2%
5.9%
自由现金流更多
OPFI
多$408.9M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
16.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $85.6M | $127.1M |
| 净利润 | $16.8M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 36.1% | -54.6% |
| 净利率 | 19.7% | — |
| 营收同比 | 5.9% | 17.1% |
| 净利润同比 | 400.3% | — |
| 每股收益（稀释后） | $1.48 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPFIZLAB
| Q4 25 | $85.6M | $127.1M | ||
| Q3 25 | $104.6M | $115.4M | ||
| Q2 25 | $100.2M | $109.1M | ||
| Q1 25 | $90.8M | $105.7M | ||
| Q4 24 | $80.8M | $108.5M | ||
| Q3 24 | $91.2M | $101.8M | ||
| Q2 24 | $86.3M | $100.1M | ||
| Q1 24 | $63.2M | $87.1M |
净利润OPFIZLAB
| Q4 25 | $16.8M | — | ||
| Q3 25 | $41.6M | $-36.0M | ||
| Q2 25 | $-20.8M | $-40.7M | ||
| Q1 25 | $-11.4M | $-48.4M | ||
| Q4 24 | $-5.6M | — | ||
| Q3 24 | $4.3M | $-41.7M | ||
| Q2 24 | $3.1M | $-80.3M | ||
| Q1 24 | $5.5M | $-53.5M |
毛利率OPFIZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率OPFIZLAB
| Q4 25 | 36.1% | -54.6% | ||
| Q3 25 | 46.3% | -42.3% | ||
| Q2 25 | 44.7% | -50.3% | ||
| Q1 25 | 46.8% | -53.3% | ||
| Q4 24 | 30.5% | -62.6% | ||
| Q3 24 | 38.5% | -66.6% | ||
| Q2 24 | 34.2% | -76.0% | ||
| Q1 24 | 8.4% | -80.7% |
净利率OPFIZLAB
| Q4 25 | 19.7% | — | ||
| Q3 25 | 39.8% | -31.2% | ||
| Q2 25 | -20.7% | -37.3% | ||
| Q1 25 | -12.5% | -45.8% | ||
| Q4 24 | -6.9% | — | ||
| Q3 24 | 4.7% | -40.9% | ||
| Q2 24 | 3.6% | -80.2% | ||
| Q1 24 | 8.8% | -61.4% |
每股收益（稀释后）OPFIZLAB
| Q4 25 | $1.48 | $-0.05 | ||
| Q3 25 | $0.77 | $-0.03 | ||
| Q2 25 | $-0.78 | $-0.04 | ||
| Q1 25 | $-0.48 | $-0.04 | ||
| Q4 24 | $-0.11 | $-0.09 | ||
| Q3 24 | $0.21 | $-0.04 | ||
| Q2 24 | $0.16 | $-0.08 | ||
| Q1 24 | $0.10 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.5M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $58.5M | $715.5M |
| 总资产 | $754.1M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OPFIZLAB
| Q4 25 | $49.5M | $689.6M | ||
| Q3 25 | $45.5M | $717.2M | ||
| Q2 25 | $45.2M | $732.2M | ||
| Q1 25 | $58.0M | $757.3M | ||
| Q4 24 | $61.3M | $779.7M | ||
| Q3 24 | $44.8M | $616.1M | ||
| Q2 24 | $46.6M | $630.0M | ||
| Q1 24 | $47.2M | $650.8M |
股东权益OPFIZLAB
| Q4 25 | $58.5M | $715.5M | ||
| Q3 25 | $49.4M | $759.9M | ||
| Q2 25 | $13.4M | $791.7M | ||
| Q1 25 | $22.6M | $810.8M | ||
| Q4 24 | $32.8M | $840.9M | ||
| Q3 24 | $34.9M | $667.7M | ||
| Q2 24 | $18.6M | $704.2M | ||
| Q1 24 | $18.2M | $762.2M |
总资产OPFIZLAB
| Q4 25 | $754.1M | $1.2B | ||
| Q3 25 | $720.6M | $1.2B | ||
| Q2 25 | $673.4M | $1.2B | ||
| Q1 25 | $640.1M | $1.2B | ||
| Q4 24 | $641.2M | $1.2B | ||
| Q3 24 | $619.3M | $985.3M | ||
| Q2 24 | $573.1M | $987.4M | ||
| Q1 24 | $563.2M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $401.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $382.2M | $-26.7M |
| 自由现金流率自由现金流/营收 | 446.6% | -21.0% |
| 资本支出强度资本支出/营收 | 22.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 23.82× | — |
| 过去12个月自由现金流最近4个季度 | $652.5M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流OPFIZLAB
| Q4 25 | $401.3M | $-26.0M | ||
| Q3 25 | $105.1M | $-32.0M | ||
| Q2 25 | $95.6M | $-31.0M | ||
| Q1 25 | $83.7M | $-61.7M | ||
| Q4 24 | $323.8M | $-55.8M | ||
| Q3 24 | $77.6M | $-26.8M | ||
| Q2 24 | $77.3M | $-42.2M | ||
| Q1 24 | $74.4M | $-90.1M |
自由现金流OPFIZLAB
| Q4 25 | $382.2M | $-26.7M | ||
| Q3 25 | $99.9M | $-35.0M | ||
| Q2 25 | $91.0M | $-33.9M | ||
| Q1 25 | $79.3M | $-63.2M | ||
| Q4 24 | $310.8M | $-58.4M | ||
| Q3 24 | $73.7M | $-28.2M | ||
| Q2 24 | $74.7M | $-42.9M | ||
| Q1 24 | $72.3M | $-91.1M |
自由现金流率OPFIZLAB
| Q4 25 | 446.6% | -21.0% | ||
| Q3 25 | 95.6% | -30.4% | ||
| Q2 25 | 90.8% | -31.1% | ||
| Q1 25 | 87.4% | -59.9% | ||
| Q4 24 | 384.6% | -53.8% | ||
| Q3 24 | 80.8% | -27.7% | ||
| Q2 24 | 86.6% | -42.9% | ||
| Q1 24 | 114.4% | -104.5% |
资本支出强度OPFIZLAB
| Q4 25 | 22.3% | 0.5% | ||
| Q3 25 | 5.0% | 2.6% | ||
| Q2 25 | 4.6% | 2.6% | ||
| Q1 25 | 4.8% | 1.5% | ||
| Q4 24 | 16.1% | 2.4% | ||
| Q3 24 | 4.3% | 1.3% | ||
| Q2 24 | 3.0% | 0.7% | ||
| Q1 24 | 3.4% | 1.1% |
现金转化率OPFIZLAB
| Q4 25 | 23.82× | — | ||
| Q3 25 | 2.52× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 18.19× | — | ||
| Q2 24 | 25.21× | — | ||
| Q1 24 | 13.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPFI
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
